What Skyrizi treats
Skyrizi (risankizumab) is a biologic medication used to treat moderate to severe plaque psoriasis, a chronic inflammatory skin condition. It is also used for other inflammatory diseases, including Crohn’s disease. Skyrizi works by targeting and inhibiting interleukin-23 (IL-23), a protein involved in the inflammatory process. This helps to reduce inflammation and improve symptoms associated with these conditions.
Benefits of Skyrizi
Patients using Skyrizi often experience significant benefits, including clearer skin with reduced plaques and improved overall skin health for those with psoriasis. For Crohn’s disease patients, Skyrizi helps to reduce gastrointestinal symptoms and induce remission. The subcutaneous injection schedule typically involves an initial dose followed by maintenance doses, allowing for manageable and effective long-term treatment.
Possible Side Effects of Skyrizi
While Skyrizi is generally well-tolerated, some patients may experience side effects, including injection site reactions such as redness, itching, or swelling. Other potential side effects include upper respiratory infections, headache, and fatigue. Serious side effects, although rare, can include an increased risk of infections and allergic reactions. It is important to monitor for any adverse effects and report them to your healthcare provider.
How infusion works at Prime
Skyrizi is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Skyrizi, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Skyrizi Work?
Skyrizi works by binding to and inhibiting IL-23, a key protein that plays a central role in the inflammatory process of plaque psoriasis and Crohn’s disease. By blocking IL-23, Skyrizi helps to reduce the inflammatory activity that contributes to skin lesions in psoriasis and intestinal inflammation in Crohn’s disease. Skyrizi is administered through subcutaneous injections, with a dosing schedule tailored to the specific condition and patient needs.
Who is Skyrizi For?
Skyrizi is suitable for adults with moderate to severe plaque psoriasis who have not responded adequately to other systemic treatments or topical therapies. It is also prescribed for adults with moderate to severe Crohn’s disease who require additional therapy. Skyrizi is recommended for individuals who need targeted therapy to manage inflammation and improve their symptoms effectively.